BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35081104)

  • 1. Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy.
    Brummer AB; Yang X; Ma E; Gutova M; Brown CE; Rockne RC
    PLoS Comput Biol; 2022 Jan; 18(1):e1009504. PubMed ID: 35081104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of glucocorticoids on the proliferation of CD19 CAR-T cells targeting B-cell tumor cell lines].
    Deng HB; Liu MJ; Jiang YY; Yuan T; Zhang R; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):747-751. PubMed ID: 34753229
    [No Abstract]   [Full Text] [Related]  

  • 5. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
    Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
    J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variables.
    Brummer AB; Xella A; Woodall R; Adhikarla V; Cho H; Gutova M; Brown CE; Rockne RC
    Front Immunol; 2023; 14():1115536. PubMed ID: 37256133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
    Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
    Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
    Song Y; Liu Q; Zuo T; Wei G; Jiao S
    Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T.
    Singh AP; Chen W; Zheng X; Mody H; Carpenter TJ; Zong A; Heald DL
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):362-376. PubMed ID: 33565700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.
    Brown CE; Rodriguez A; Palmer J; Ostberg JR; Naranjo A; Wagner JR; Aguilar B; Starr R; Weng L; Synold TW; Tran V; Wang S; Reik A; D'Apuzzo M; Ressler JA; Zhou Y; Mendel M; Gregory PD; Holmes MC; Tang WW; Forman SJ; Jensen MC; Badie B
    Neuro Oncol; 2022 Aug; 24(8):1318-1330. PubMed ID: 35100373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Salinas RD; Durgin JS; O'Rourke DM
    CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T Cells.
    Tudor T; Binder ZA; O'Rourke DM
    Neurosurg Clin N Am; 2021 Apr; 32(2):249-263. PubMed ID: 33781506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
    Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
    J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
    Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
    Front Immunol; 2020; 11():99. PubMed ID: 32117253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging.
    Xie T; Chen X; Fang J; Xue W; Zhang J; Tong H; Liu H; Guo Y; Yang Y; Zhang W
    Cytotherapy; 2021 Mar; 23(3):211-222. PubMed ID: 33334686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
    Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
    Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.